Hematology | Prof. Huang Xiaojun Elected as an Academician of the Chinese Academy of Engineering
黄晓军教授当选中国工程院院士

2023-11-26

On November 22, 2023, Professor Huang Xiaojun from Peking University People's Hospital (PKUPH) was elected as an academician of the Chinese Academy of Engineering (CAE).

Currently serving as the director of the Peking University Institute of Hematology at PKUPH, Professor Huang Xiaojun is a member of the Academic Advisory Committee of the Chinese Academy of Medical Sciences (CAMS) and a foreign corresponding member of the French National Academy of Sciences. Over his 36-year medical career, Professor Huang has been at the forefront of clinical work and research, leading his team to break through international barriers in semi-matched transplantation, establishing a new therapy for leukemia treatment, the "Beijing Protocol"， with his team.

This new therapy addressed the global medical challenge of insufficient donor sources for bone marrow transplantation and significantly advanced leukemia treatment worldwide. In 2016, the European Society for Blood and Marrow Transplantation recognized this breakthrough as the "Beijing Protocol". Currently, the "Beijing Protocol" has become the predominant hematopoietic stem cell transplantation therapy in China and has made PKUPH the world's largest haploidentical transplantation center.

Up to now, PKUPH has boasted four academicians of the Chinese Academy of Engineering. Professor Lu Daopei was elected in 1996, followed by Professor Wang Jun in 2019, Professor Jiang Baoguo in 2021, and now Professor Huang Xiaojun in 2023.